Study Enabled by 10x Genomics Single Cell and Spatial Technologies Explains Why Immunotherapy is More Effective for Certain Brain Tumors Than Others

Researchers uncover mechanisms behind divergent responses to immune checkpoint blockade between primary and metastatic brain tumors PLEASANTON, Calif., Sept. 5, 2023 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its…

Click here to view original post